December 6, 2011
In a private, closed door meeting, Stephen J. Petti, CEO of Hibernaid, Inc. discussed Hibernaid’s pharmaceutically-induced hypothermia program for the treatment of post-cardiac arrest, which may also have potential in treating stroke, traumatic brain injury, spinal cord injury and other medical conditions where survival and neurological function are at risk.
George Damis Yancopoulos M.D., Ph.D.
Chief Scientific Officer & Founding Scientist
Interleukin Genetics – Lewis Bender, Chief Executive Officer
Egenix – Jedd Levine, Chief Medical Officer
Cytosorbents Inc. – Phillip Chan, Chief Executive Officer & President (update)